Creative Medical Technology Holdings (CELZ) Non Operating Income (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Non Operating Income of $55436.0 for Q1 2026, up 147.69% year-over-year from $22381.0 in Q1 2025, and down 4.6% quarter-over-quarter from $58108.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Non Operating Income (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Non Operating Income for 14 consecutive years, with $55436.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 147.69% year-over-year to $55436.0; the TTM figure through Mar 2026 stood at $180861.0 (down 5.39% YoY), while the FY2025 annual figure was $147806.0, down 40.97% from the prior year.
- Non Operating Income fell to $55436.0 in Q1 2026 per CELZ's latest filing, from $58108.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $93265.0 in Q4 2023 and bottomed at $22381.0 in Q1 2025.
- Historically, Non Operating Income has averaged $59167.2 across 5 years, with a median of $61147.0 in 2023.
- Annual changes were most pronounced in 2025 — Non Operating Income plunged 72.57% — and 2026, when it surged 147.69%.
- Creative Medical Technology Holdings' Non Operating Income stood at $62245.0 in 2022, then jumped by 49.84% to $93265.0 in 2023, then slumped by 66.05% to $31660.0 in 2024, then soared by 83.54% to $58108.0 in 2025, then fell by 4.6% to $55436.0 in 2026.
- Business Quant data shows CELZ's Non Operating Income at $55436.0 in Q1 2026, $58108.0 in Q4 2025, and $37100.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | 50,913.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50,913.00 |
| Mar 31, 2026 | 55,436.00 |
| Dec 31, 2025 | 58,108.00 |
| Sep 30, 2025 | 37,100.00 |
| Jun 30, 2025 | 30,217.00 |
| Mar 31, 2025 | 22,381.00 |
| Dec 31, 2024 | 31,660.00 |
| Sep 30, 2024 | 69,539.00 |
| Jun 30, 2024 | 67,578.00 |
| Mar 31, 2024 | 81,603.00 |
| Dec 31, 2023 | 93,265.00 |
| Sep 30, 2023 | 89,233.00 |
| Jun 30, 2023 | 89,913.00 |
| Mar 31, 2023 | 61,147.00 |
| Dec 31, 2022 | 62,245.00 |
| Sep 30, 2022 | 38,083.00 |
| Dec 31, 2021 | -2.40 Mn |
| Sep 30, 2021 | -1.01 Mn |
| Jun 30, 2021 | -2.39 Mn |
| Mar 31, 2021 | 28.14 Mn |